Centre for Rheumatic Diseases, Division of Immunology, Infection and Inflammation, 120 University Place Glasgow, G12 8TA, U.K.
Best Pract Res Clin Rheumatol. 2010 Aug;24(4):479-87. doi: 10.1016/j.berh.2010.01.004.
Current therapeutics for the treatment of rheumatoid arthritis (RA) offer limited efficacy in a restricted number of patients. There is, therefore, an unmet clinical need for the development of more efficacious therapeutics for the treatment of disease. Anti-TNFalpha therapy has provided proof of principle that cytokine blockade is an appropriate strategy by which to inhibit disease progression. In this review, we describe the basic biology of potential novel cytokine targets and the results of recent clinical trials, with particular focus on the cytokines related to Th17 biology, namely interleukin (IL)-12, IL-23 and IL-17, in addition to the TNF superfamily and the adipocytokines.
目前治疗类风湿关节炎（RA）的方法在疗效上存在局限，且适用人群有限。因此，我们需要开发更有效的治疗方法来治疗这种疾病。抗 TNFα 治疗为细胞因子阻断是抑制疾病进展的一种合适策略提供了原理证明。在这篇综述中，我们描述了潜在新型细胞因子靶点的基础生物学以及最近临床试验的结果，特别关注与 Th17 生物学相关的细胞因子，即白细胞介素（IL）-12、IL-23 和 IL-17，此外还关注了 TNF 超家族和脂肪细胞因子。
